http://www.lsis.com/goto/r96/rss 2010-06-23T11:10:56+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FB%12u%7E%7D During early preclinical development of therapeutic proteins, representative materials are often required for process development, such as for pharmacokinetic/pharmacodynamic studies in animals, formulation design, and analytical assay development. To rapidly generate large amounts of representative materials, transient transfection is commonly used. Because of the typical low yields with transient transfection, especially in CHO cells, here we describe an alternative strategy using stable transfection pool technology. Using stable transfection pools, gram quantities of monoclonal antibody (Mab) can be generated within 2 months post-transfection. Expression levels for monoclonal antibodies (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FB%11t%7F%7D CAMBRIDGE, Mass.-(BUSINESS WIRE)-Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the election of Eve E. Slater, M.D., F.A.C.C., to the Company's Board of Directors as a class III director. Dr. Slater is board certified in internal medicine and cardiology and has extensive experience in the pharmaceutical industry, most recently serving as senior vice president for worldwide policy at Pfizer, Inc. Prior to joining Pfizer, she served in senior management positions at Merck Research Laboratories. In addition, Dr. Slater was the Assistant Secretary for Health and served as chief health policy advisor for the U.S. Department of Health and Human Services. Idera has created a strong (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FB%11%7Bv%7C SOPHIA ANTIPOLIS, FRANCE-(Marketwire - June 21, 2010) - Highlighted Links companynewsgroup Home Page www.nicox.com NicOx S.A. (NYSE Euronext Paris: COX) today announced that additional naproxcinod clinical data were presented at the Annual European Congress of Rheumatology, the annual conference of the European League Against Rheumatism (EULAR), which took place from June 16 to June 19 in Rome, Italy. Two posters on clinical results for naproxcinod were presented. The abstracts are available on the congress website (www.eular.org/congress_home.cfm). Naproxcinod is the first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug-candidate developed for the (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v96/%3B%97f%FB%14%7Ew%7C The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted. Scientists at Washington University School of Medicine in St. Louis and Merck & Co. Inc studied the effects of a class of drugs known as gamma secretase inhibitors. Researchers had worried that these drugs might cause a build-up of proteins linked to Alzheimer's disease and that this build-up could be unleashed in a surge when patients went off the medications. But the new study suggests that they do not. "This is important because it eases some concerns that have been raised about this potentially useful (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FB%14%7E%7F%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d7d20e/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition" report to their offering. Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The report provides a detailed understanding and analysis of how and why companies enter (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/goto/v96/%3B%97f%FC%12y%7Bs ScienceDaily (June 17, 2010) The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted. See Also: Health & Medicine Alzheimer's Research Multiple Sclerosis Research Healthy Aging Mind & Brain Dementia Alzheimer's Multiple Sclerosis Reference Amyloid Dementia with Lewy bodies Penicillin-like antibiotics COX-2 inhibitor Scientists at Washington University School of Medicine in St. Louis and Merck & Co. Inc studied the effects of a class of drugs known as gamma secretase inhibitors. Researchers had worried that these drugs might cause a build-up of proteins linked to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FC%12%7E%7Ex CAMBRIDGE, Mass.-(BUSINESS WIRE)-Genzyme Corporation (NASDAQ: GENZ) announced that all 10 members of its board of directors were re-elected at its annual meeting of shareholders today. Shareholders also approved all of the company s proposals, including those regarding equity plans and the employee stock purchase program. In addition, the board voted to appoint three new directors. Genzyme s board appointed Dennis M. Fenton, Ph.D., a highly regarded industry leader in manufacturing and 25-year veteran of Amgen Inc., as a director. The appointment fulfills the commitment made by Genzyme as part of its agreement with Relational Investors, LLC to nominate an independent director recommended (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FC%12%7Dws DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f241be/merck_co_inc) has announced the addition of the "Merck & Co., Inc. - SWOT Analysis" company profile to their offering. Merck & Co., Inc. - SWOT Analysis The Merck & Co., Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. Merck & Co., Inc. - SWOT Analysis examines the companys key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Merck & Co. is one of the research driven Big Pharma companies. The company is engaged in research, manufacturing and marketing of drugs and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FC%12%7D%7F%7B DARMSTADT, Germany-(BUSINESS WIRE)-Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax (BLP25 liposome vaccine)* clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, STARTa and INSPIREb. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees. The resumption of the BLP25 liposome vaccine clinical program is very good news for the oncology community and NSCLC patients. If the START and INSPIRE Phase III trials are successful, BLP25 liposome vaccine could play an important role in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FC%11x%7D%7C PURPOSE: We assessed U.S. physicians' attitudes and perceptions regarding potential human papillomavirus (HPV) vaccination of males. METHODS: We surveyed a random sample of 2,714 pediatricians and family practitioners identified in administrative claims of a U.S. health plan as HPV vaccinators of females; 595 pediatricians and 499 family practitioners participated. RESULTS: Most physicians would recommend HPV vaccination to males aged 11-12 (63.9%), 13-18 (93.4%), and 19-26 (92.7%) years. Physicians agreed that males should be vaccinated to prevent them from getting genital and anal warts (52.9% strongly and 36.0% somewhat) and to protect females from cervical cancer (75.3% strongly and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FC%16%7Bzy Disclosure limitation is an important consideration in the release of public use data sets. It is particularly challenging for longitudinal data sets, since information about an individual accumulates with repeated measures over time. Research on disclosure limitation methods for longitudinal data has been very limited. We consider here problems created by high ages in cohort studies. Because of the risk of disclosure, ages of very old respondents can often not be released; in particular, this is a specific stipulation of the Health Insurance Portability and Accountability Act (HIPAA) for the release of health data for individuals. Top-coding of individuals beyond a certain age is a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FC%17%7F%7Ex The widespread emergence of antibiotic resistant bacteria and lack of new pharmaceutical development has catalyzed a need for new and innovative approaches for antibiotic drug discovery. One bottleneck in antibiotic discovery is the lack of a rapid and comprehensive method to identify compound mode of action (MOA). Since a hallmark of antibiotic action is as inhibitors of essential cellular targets and processes, we identify a set of 308 essential genes in the clinically important pathogen Staphylococcus aureus. For these genes 446 differentially expressing strains were constructed in a comprehensive platform of sensitized and resistant strains. A subset of strains either allows target (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FD%1Cu%7Cx ROME, June 17, 2010 (GLOBE NEWSWIRE) - XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines. All seven patients who enrolled in the trial displayed rapid reduction of intraocular inflammation and improvement in visual acuity or other ophthalmic measures following a single treatment with XOMA 052, a therapeutic antibody candidate that inhibits the inflammatory cytokine interleukin-1 beta (IL-1 beta). The preliminary results of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FD%1Ct%7C%7D ROCKLAND, Mass.-(BUSINESS WIRE)-EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that they are resuming their Stimuvax (BLP25 liposome vaccine)* clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, STARTa and INSPIREb. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees. œMerck KGaA remains highly committed to the development of BLP25 liposome vaccine and the well-being of the patients. We believe this therapeutic cancer vaccine has the potential to be a valuable addition to the future range of therapies for oncologists (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FD%1C%7Bwz June 17 (Bloomberg) - Merck & Co. plans to cut about 800 jobs in France, or 20 percent of its workforce in the country, following its purchase of Schering-Plough last year, French daily La Tribune reported, citing management and unions. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FD%1C%7Bv%7E Schizophrenia played a prominent role at this year's American Psychiatric Association Annual Meeting due to the prevailing high level of unmet need. Merck & Co and Dainippon Sumitomo presented data for new drugs which Datamonitor believes represent important additions to the current treatment portfolio. Elsewhere, an interesting lecture predicted a future of personalized schizophrenia treatments. Dainippon Sumitomo: lurasidone Phase III data validates potential This year's American Psychiatric Association meeting (APA 2010) provided an opportunity for attendees to assess the potential of Dainippon Sumitomo's lurasidone ahead of its expected approval in late 2010. At the meeting, the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FD%1C%7B%7F%7C MECHELEN, BELGIUM-(Marketwire - June 17, 2010) - Galapagos NV (Euronext: GLPG) announced that Kempen and Co. placed nearly 1.3 million Galapagos shares (5.4% of total outstanding shares) through an accelerated bookbuilding today. These shares were held by Apax, who obtained their position in Galapagos through the venture capital financing round in 2002. The shares were placed with European institutional investors. "I am very pleased that there is so much institutional investor interest in Galapagos and that this placement could be executed in only a couple of hours. We thank Apax for their support as a shareholder over the past eight years and welcome the new shareholders," said Onno van (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FD%11y%7F%7C PLAN-LES-OUATES GENEVA, SWITZERLAND-(Marketwire - June 15, 2010) - Addex Pharmaceuticals / Addex's ADX48621 Effective in Preclinical Parkinson's Disease Studies processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Presented at the International Congress of Parkinson's Disease and Movement Disorders Geneva, Switzerland, 15 June 2010 - Allosteric modulation company Addex Pharmaceuticals Ltd (SIX: ADXN) today presented encouraging data from preclinical studies demonstrating the anti-Parkinson's effects of ADX48621, a novel drug candidate that has completed three Phase I clinical trials. Addex presented preclinical data at the 14(th) (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FD%11%7E%7B%7C LOS ANGELES-(BUSINESS WIRE)-ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that Dr. Rahul Singhvi has been appointed to the company s Board of Directors. Dr. Singhvi is currently the President and Chief Executive Officer of Novavax, Inc. (NASDAQ: NVAX), a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. His appointment increases the number of independent directors to five. I am excited about joining ImmunoCellular s Board of Directors and look forward to supporting the development of its portfolio of promising cancer vaccines and immunotherapies Dr. Singhvi is a recognized vaccine specialist, (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v96/%3B%97f%FD%11%7Cz%7F 14.06.2010 - Patheon announced that it has signed an expanded contract manufacturing agreement with Merck & Co., Inc. "We have developed a great partnership with Merck and are very pleased that they have chosen to expand it with this contract manufacturing agreement," said Wes Wheeler, Chief Executive Officer and President of Patheon Inc. "We are 100 percent focused on being the best service provider to our clients. This expanded contract with Merck validates that we are making great progress towards meeting this goal." The expanded agreement solidifies Patheon as a key preferred supplier to Merck. Patheon's projects and services will be delivered to Merck from eight of Patheon's global (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v96/%3B%97f%FD%16uvr Representatives from more than 50 countries attended the Sixth Meeting of the Global Alliance to Eliminate Lymphatic Filariasis (GAELF) in Seoul last week, to review the progress of the Global Programme to Eliminate Lymphatic Filariasis (Global Programme), which seeks to eliminate the disease by 2020. Lymphatic Filariasis (LF), one of the major neglected tropical diseases (NTDs), is on track to become one of the first parasitic diseases transmitted by a mosquito to be eliminated. More than 1 billion people in 80 countries are at risk for LF, commonly referred to as 'elephantiasis.' The debilitating and disfiguring disease causes extreme swelling of the legs and, in men, often the scrotum, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FD%14yzy Liver cytochrome P450s (P450s) play critical roles in drug metabolism, toxicology, and metabolic processes. Despite rapid progress in the understanding of these enzymes, a systematic investigation of the full spectrum of functionality of individual P450s, the interrelationship or networks connecting them, and the genetic control of each gene/enzyme is lacking. To this end, we genotyped, expression-profiled, and measured P450 activities of 466 human liver samples and applied a systems biology approach via the integration of genetics, gene expression, and enzyme activity measurements. We found that most P450s were positively correlated among themselves and were highly correlated with known (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FD%14%7F%7Cz Inhibition of CCR2 has been considered as a target for multiple therapeutic diseases including autoimmune disease, atherosclerosis, pain, and metabolic disease, based in part on the critical role this receptor plays on monocyte migration. Numerous companies have reported programs to identify CCR2 antagonists. Common challenges to the development of CCR2 agents have included poor activity at the rodent receptor and selectivity for both other chemokine receptors and ion channels. This review summarizes the rationale for targeting CCR2 in disease, the recent progress in the identification of potent and select CCR2 antagonists, and the current status of clinical trials for CCR2 agents. |-| (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FD%15x%7F%7C The growing rate of obesity and diabetes, and an aging population has led to increased demand for new antihypertensive compounds. This review highlights the challenges and opportunities associated with each phase of drug discovery and development of novel antihypertensive agents. Discovery and development starts with identification of a protein hypothesized to be linked to hypertension. Using the information gathered during this early stage, several potential candidates are often synthesized and moved on through preclinical evaluations, eventually leading to selection of one or more compounds for testing in humans. The compounds then enter preclinical safety studies in laboratory animal (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FE%1C%7Ey%7B In response to reported cases of vaccine-acquired rotavirus infection in infants with severe combined immunodeficiency (SCID) following rotavirus vaccine administration, both Merck & Co. and GlaxoSmithKline Biologicals have revised the prescribing information and patient labeling for their respective rotavirus vaccine products, pentavalent rotavirus vaccine (RV5) and monovalent rotavirus vaccine (RV1), with approval from the Food and Drug Administration. Merck revised the prescribing information and patient labeling for RV5 in December 2009, and GlaxoSmithKline Biologicals did so for RV1 in February 2010. After the revision to the RV5 prescribing information, CDC sought consultation from (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FE%1Dyz%7B (Headache 2010;*:*-*) Background.- Although diagnostic rates for migraine have increased over the past 5 years, the proportion of migraine sufferers using triptans has remained essentially stable. Objectives.- To assess the rate of onset of new triptan prescriptions among persons with migraine and the predictors of initiating therapy. Methods.- The American Migraine Prevalence and Prevention Study is a longitudinal study conducted in a representative sample of headache sufferers in the US population. Episodic migraineurs not using triptans in 2005 who continued to have migraine and provided treatment data in 2006 (n = 6865) were included. We assessed predictors of triptan use in (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v96/%3B%97f%FE%12%7Fxr A new US study suggests that post-surgery infection by the bacterium Staphylococcus aureus (Staph), a type commonly acquired in hospital settings, is more likely to occur after operations to the chest and head than other major procedures. The retrospective cohort study is available to read online and is due to appear in the July print issue of the journal Infection Control and Hospital Epidemiology. Lead author Dr Deverick Anderson, an infectious diseases specialist at Duke University Medical Center in Durham, North Carolina, told the media that: "We found that chest and head procedures accounted for the majority of staph infections after major surgery." Anderson and colleagues analyzed (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FE%13uv%7E GERMANTOWN, Md.-(BUSINESS WIRE)-Psyadon Pharmaceuticals, Inc. announces today the opening of a clinical research site at the University of California at San Diego headed by Dr. William Nyhan. He joins Dr. Hyder Jinnah at Emory University to study the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with Lesch-Nyhan Disease (LND). Since ecopipam works selectively on the dopaminergic system, I believe it has the potential to significantly impact the disease, and I am very excited to participate in the clinical trial. Dr. Nyhan (in collaboration with Dr. Michael Lesch) was the first to definitively report this disease (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FE%11%7E%7C%7E BACKGROUND: We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with the risk of infection reappearance following a period of nondetection. METHODS: Women (1,788) ages 16 to 23 years underwent cytologic testing and PCR-based testing of cervical swab samples for HPV DNA (HPV-16/18/31/33/35/45/52/58/59) at approximately 6-month intervals for up to 4 years in the context of a phase 3 clinical trial (placebo arm). HPV type-specific incidence rates were estimated per 100 person-years. Duration of type-specific cervical infection episodes and risk of reappearance following a period of nondetection were estimated using Kaplan-Meier methods. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FE%16uyy J Med Chem. |-| Palucki M, Higgins JD, Kwong E, Templeton AC. |-| Basic Pharmaceutical Sciences, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania 19486. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FE%15x%7C%7D NEW YORK-(BUSINESS WIRE)-The International Quality and Productivity Center (IQPC) is pleased to announce the newest installment of the Asthma & COPD Event, scheduled for June 28 30, 2010, at the Ritz Carlton Philadelphia, Philadelphia, PA. LABA safety in COPD and Asthma: A Brief Regulatory Overview. Representatives from many leading innovators will be joining the speaking faculty, including speakers from Novartis and Merck, who have worked very closely with the FDA to assess the guidance provided in the FDA s February communication regarding Long-Acting Beta-Agonists (LABAs), which have recently been proven to improve asthma symptoms when used appropriately with an asthma controller (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FE%15x%7E%7F TRENTON, N.J.-(BUSINESS WIRE)-BioNJ, New Jersey s trade association for the biotechnology industry, will hold its 2010 BioPartnering Conference on June 14 and 15 at the Westin Princeton at Forrestal Village, in Princeton, NJ. New Jersey s only biopartnering conference, the two-day meeting will provide a valuable opportunity for biotechnology and pharmaceutical companies located in New Jersey and beyond to discuss partnerships, licensing agreements and other collaborative efforts, and will include keynote speakers from Johnson & Johnson, Merck & Co., Inc, Pfizer, sanofi-aventis US and Defined Health. This is a significant opportunity for New Jersey s biotechnology firms to network with (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FF%1Cyzx Summary Weight loss follows when adult humans enter a phase of negative energy balance brought about by reducing energy intake and/or increasing energy expenditure. The weight loss period is usually viewed as a continuous process, ending when energy equilibrium is achieved at a lower weight or with death following depletion of fuel stores. However, growing evidence supports the expanded view that induction of negative energy balance leads to well-defined physiological effects characterized by three discrete phases (I-III). At present there are no comprehensive reviews of the 'early' phase of weight loss, a gap highlighted by recent interest in rapidly testing new treatments with short-term (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FF%12xxr TRENTON, N.J.-(BUSINESS WIRE)-BioNJ, New Jersey s trade association for the biotechnology industry, will hold its 2010 BioPartnering Conference on June 14 and 15 at the Westin Princeton at Forrestal Village, in Princeton, NJ. New Jersey s only biopartnering conference, the two-day meeting will provide a valuable opportunity for biotechnology and pharmaceutical companies located in New Jersey and beyond to discuss partnerships, licensing agreements and other collaborative efforts, and will include keynote speakers from Johnson & Johnson, Merck & Co., Inc, Pfizer, sanofi-aventis US and Defined Health. text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v96/%3B%97f%FF%12x%7E%7D 08.06.2010 - Pieris AG announced that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both pharma and biotech experience, with extensive expertise in therapeutic protein drug development. Over the course of his career, Dr. Audoly has held research and managerial positions of increasing responsibility, first as Senior Research Scientist, Department of Inflammation, at Pfizer Inc. and then as Senior Research Fellow, Department of Pharmacology, at Merck & Co. Inc. He then joined MedImmune Inc. as Director R&D Inflammation and most recently held the position at (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FF%13u%7Ex CHICAGO & ROCKLAND, Mass.-(BUSINESS WIRE)-Abstract numbers: 2010, TPS151, TPS152 We are excited about the results of this study, in that patients were able to receive cilengitide beyond six months with no treatment-related severe adverse events. Moreover, 10% of patients were still alive after four years. EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data showed that treatment of 15 patients with the investigational integrin-inhibitor for more (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FF%13u%7Ez CHICAGO & DARMSTADT, Germany-(BUSINESS WIRE)-ASCO Abstract Numbers: 2010, TPS151, TPS152 We are excited about the results of this study, in that patients were able to receive cilengitide beyond six months with no treatment-related severe adverse events. Moreover, 10% of patients were still alive after four years. Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data showed that treatment of 15 patients with the investigational integrin-inhibitor for more (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FF%11%7F%7E%7B SAN MATEO, Calif.-(BUSINESS WIRE)-Deltagen, Inc. (Pink Sheets:DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended March 30, 2010. Management s Discussion and Analysis of Financial Conditions and Results of Operations Revenues: The Company s consolidated revenues for the three months ended March 30, 2010 totaled $0.499 million. The revenues in the first quarter were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company s DeltaOneTM program. Interest Income: (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FF%11%7Dwr Objective. To determine the epidemiological characteristics of postoperative invasive Staphylococcus aureus infection following 4 types of major surgical procedures. Design. Retrospective cohort study. Setting. Eleven hospitals (9 community hospitals and 2 tertiary care hospitals) in North Carolina and Virginia. Patients. Adults undergoing orthopedic, neurosurgical, cardiothoracic, and plastic surgical procedures. Methods. We used previously validated, prospectively collected surgical surveillance data for surgical site infection and microbiological data for bloodstream infection. The study period was 2003 through 2006. We defined invasive S. aureus infection as either nonsuperficial (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97f%FF%17x%7Fs Dalotuzumab (MK-0646; h7C10), being developed by Merck & Co Inc under license from Pierre Fabre SA, is a recombinant humanized IgG1 mAb against the IGFR1 for the potential intravenous treatment of cancer. Preclinical studies have demonstrated that dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGFR1 autophosphorylation and Akt phosphorylation. In multiple cancer cell lines and in mouse xenograft models, dalotuzumab displayed significant antitumor activity, in particular against NSCLC and breast cancer. In addition, coadministration of dalotuzumab with other anticancer agents, such as taxanes, enhanced the in vitro and in vivo antitumor activity of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FF%14%7F%7Dx SAN DIEGO, CA-(Marketwire - June 04, 2010) - Highlighted Links Accelrys Accelrys, Inc. (NASDAQ: ACCL), a leading scientific informatics software and services company, today announced that Accelrys experts will present at two conferences the week of June 7th. On Tuesday, June 8, 2010, Cambridge Network's IT Special Interest Group meets to discuss 'Cloud computing - challenges to providing bullet-proof IT services through the cloud'. At this event, which takes place at Microsoft Research, Roger Needham Building, Cambridge, UK at 6:00 pm, Conrad Agramont from Accelrys will be speaking about the company's cloud computing strategies and how the cloud affects scientists and software makers. On (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FF%14%7F%7Fs LEIDEN, NETHERLANDS-(Marketwire - June 04, 2010) - Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that the Annual General Meeting of Shareholders (AGM) held today in Leiden adopted the 2009 financial statements. In addition, the AGM reappointed Mr. J.P. Oosterveld as member of the Supervisory Board; Mr. W. Burns, Mr. J. Shannon and Mr. G. Siber were appointed as new members of the Supervisory Board. The shareholders of Crucell were represented in person, by proxy voting, or by voting instruction, representing a total of 36,2% of the total issued share capital entitled to vote. The shareholders approved the appointments of Mr. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97f%FF%14%7F%7F%7C SOPHIA ANTIPOLIS, FRANCE-(Marketwire - June 04, 2010) - Highlighted Links companynewsgroup Home Page www.nicox.com NicOx S.A. (NYSE Euronext Paris: COX) wishes to remind its shareholders that its shareholder meetings are convened on second call on Wednesday June 16, 2010 at 10:00 am CET at the Company's headquarters. NicOx wishes to ask its shareholders to support the Company by voting at the shareholder meetings. To participate in NicOx's shareholder meetings, shareholders are kindly requested to send to NicOx a share certificate ('attestation de participation') dated June 11 at the latest to be issued by the bank or financial intermediary holding the shares (in bearer form). (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97f%FF%15u%7Ey CHICAGO-(BUSINESS WIRE)-Today, Merck announced the launch of the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatment and prevention of cancer. The global network comprises leading cancer research centers who will partner with Merck to speed the development of innovative treatments for a range of cancers. A first-in-man trial of poly (ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with anti-tumor activity in BRCA-deficient and sporadic ovarian cancers. Cancer is a diverse group of diseases that accounts for 7.4 million deaths (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97g%F6%12%7Fwy CHICAGO-(BUSINESS WIRE)-Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy. The regimen containing 150 mg fosaprepitant dimeglumine was not inferior to the regimen with oral aprepitant. Results of the study, known as EASE-017, will be presented on June 8th at the 2010 American (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97g%F6%12%7F%7E%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/5516f7/the_future_of_opht) has announced the addition of the "The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets" report to their offering. The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets, provides in-depth analysis of the unmet needs, drivers and barriers that impact the global ophthalmology (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v96/%3B%97g%F6%12%7Ev%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ed89f5/a_decision_support) has announced the addition of the "A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market" report to their offering. A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v96/%3B%97g%F6%14%7F%7Ds SOPHIA ANTIPOLIS, FRANCE-(Marketwire - June 01, 2010) - Highlighted Links companynewsgroup Home Page www.nicox.com NicOx S.A. (NYSE Euronext Paris: COX) today announced that two drug candidates, representing new classes of nitric oxide (NO)-donating compounds based on the Company's NO-donating R&D platform, have moved into preclinical research with preclinical data presented at scientific conferences for the first time. NCX 434 - a preclinical candidate in Diabetic Macular Edema Results showing NCX 434 improved oxygen saturation in the eye compared to reference were presented at an oral session of the Ocular Diseases & Drug Discovery conference in Boston, on May 28. These results were (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97g%F6%15x%7Fx On October 16, 2009, the Food and Drug Administration licensed quadrivalent human papillomavirus vaccine (HPV4; Gardasil, Merck & Co. Inc.) for use in males aged 9 through 26 years for prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. HPV4 had been licensed previously for use in females aged 9 through 26 years for prevention of HPV 6, 11, 16, and 18-related outcomes (i.e., vaginal, vulvar, and cervical precancers and cancers and genital warts). The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of females at age 11 or 12 years and catch-up vaccination for females aged 13 through 26 years. On October 21, 2009, ACIP provided (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v96/%3B%97g%F7%1Cxxx On October 16, 2009, the Food and Drug Administration (FDA) licensed bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 through 25 years. Cervarix is the second human papillomavirus (HPV) vaccine licensed for use in females in the United States. Quadrivalent HPV vaccine (HPV4; Gardasil, Merck & Co, Inc.) was licensed in 2006 for use in females aged 9 through 26 years, and the Advisory Committee on Immunization Practices (ACIP) recommended routine HPV4 vaccination of females aged 11 or 12 years, and catch-up vaccination for females aged 13 through 26 years. This report provides updated recommendations for routine and catch-up vaccination of (…)